|Articles|April 13, 2022
Improving Titer, Quality and Efficiency of AAV Manufacturing and Production by Optimizing Osmolality
Author(s)Advanced Instruments
Modulating osmolality in the early stages of AAV1 upstream manufacturing, can result in improved outcomes such as overall yield, quality, reduced manufacturing costs and improved efficiencies.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Samsung Biologics Bolsters US Manufacturing Network with GSK Facility Buy
2
Novel Delivery Approaches of Biopharmaceuticals 2025
3
GSK and CAMP4 Partner to Advance RNA-Targeting Therapeutics
4
EMA Director Highlights Agency Achievements in 2025
5